- More
- Back
Exome Asset Management is an innovative asset management company focused on investing in public markets across the worldwide healthcare industry, including pharmaceuticals, biopharmaceuticals, healthcare services, and medical devices.
The firm practices two existing investment strategies: one which invests broadly across worldwide healthcare subsectors and geographies, and another that is a specialized healthcare investment fund emphasized on public company opportunities in emerging markets.
Exome Asset Management’s investment strategies are broadly diversified by geography and subsector.
Companies dedicated to the discovery, development, production and commercialization of drugs and other medications.
Companies focused on the discovery of new therapeutics, including gene and cell therapy products approaching the market.
Companies that design, manufacture and distribute instruments, consumables, reagents, and various other life science tools and services.
Companies that develop equipment used to prevent, detect, diagnose or treat an illness or disease.
Companies dedicated to facilitating treatment, including by providing care, physical facilities, or the distribution of necessary materials.
Companies involved with various other aspects of the healthcare industry.
Exome employs a staff of investment professionals and support staff committed to investing for a healthier world.
Samuel D. Isaly is Managing Partner and Founder of Exome. Mr. Isaly is an experienced healthcare fund manager and has been active in global healthcare investing and analysis for over 45 years.
Over the course of his career, Mr. Isaly has been a pharmaceutical analyst with Chase Manhattan Bank, Merrill Lynch, Legg Mason, and S.G. Warburg. In 1989, Mr. Isaly launched OrbiMed Advisors LLC. During his time at OrbiMed, Mr. Isaly was the portfolio manager of Worldwide Healthcare Trust Plc for 22 years.
Mr. Isaly received an A.B. in Economics from Princeton University and a M.Sc. (Economics) from The London School of Economics.
Focus Area: Developed and Emerging Markets Healthcare
Contact: IsalyS@exomeasset.com
Carlos M. Godoy is the Chief of Staff at Exome. Prior to joining Exome in June 2018, Mr. Godoy worked at OrbiMed Advisors LLC, where he served in an administrative role reporting directly to Mr. Isaly. Prior to OrbiMed, he was a Vice President in Client Service at JPMorgan Chase & Co. Mr. Godoy began his career in the International Training Department at Givenchy. He attended the University of Miami (FL), where he majored in International Relations and Political Science.
Focus Area: Human Resources & Administrative
Contact: GodoyC@exomeasset.com
Joseph Narvaez is the Chief Technology Officer at Exome. Prior to joining Exome in 2018, Mr. Narvaez served as a Network Manager at OrbiMed Advisors LLC, where he managed the firm’s IT systems. Prior to OrbiMed, he was a Systems Analyst at Fidessa Corporation. Mr. Narvaez received his B.S. in Information Technology from the University of Scranton and currently holds a number of industry certifications.
Focus Area: Information Technology (IT) & Accounting
Contact: NarvaezJ@exomeasset.com
Meredith Hagen is the Compliance Officer of Exome. Prior to joining Exome in 2019, Ms. Hagen worked at OrbiMed Advisors LLC, where she served in a compliance role. Prior to OrbiMed, she held compliance and administrative roles at Lazard and Lazard Asset Management LLC. Ms. Hagen began her career in the legal department at Sony Corporation of America. She received a B.A. from Hunter College and an MBA from Pace University.
Contact: hagenm@exomeasset.com
Alex Forschner has been responsible for raising capital for early and late stage venture-backed companies across a variety of market sectors over his 15 years career. Mr. Forschner’s capital raising efforts came from an exclusive investor network of individuals, foreign corporations, family offices and foundations. In addition, he was responsible for sourcing and structuring multiple transactions. Mr. Forschner earned a B.S. from the University of Arizona.
Christina Maida is an Investment Analyst and Trader working alongside Mr. Isaly to execute Exome’s worldwide healthcare investing strategy. Ms. Maida has been with Exome since its inception in June 2018. She focuses on biotech, pharma, life science tools, and medical devices in the United States and Europe. Ms. Maida received her B.A. from Princeton University and is a Master’s candidate at New York University, studying Financial Management.
Focus Area: Worldwide healthcare investing
Contact: MaidaC@exomeasset.com
Wongmo Kang is an Investment Analyst at Exome specializing in emerging markets healthcare. His primary focus is on Korean and ASEAN healthcare. Prior to joining Exome in 2018, Mr. Kang worked as a strategy consultant at Deloitte & Touché LLP. He also previously served in the US 8th Army and worked at Mercer LLC. Mr. Kang received a B.S. and a M.S. from NYU Stern School of Business.
Focus Area: Emerging markets healthcare investing, including in Korea, Japan, Singapore, Malaysia, and Thailand
Contact: KangW@exomeasset.com
Yiqi Liu is an Investment Analyst at Exome, covering investment opportunities across all healthcare subsectors in the Greater China region. Prior to joining Exome in 2019, he interned in the investment banking divisions at BNP Paribas and Citi Orient Securities, where he actively participated in several M&A and IPO transactions in the Chinese capital market. Mr. Liu received a B.A. in Economics from Franklin & Marshall College and an M.A. in Economics from Columbia University.
Focus Area: Emerging markets healthcare investing, especially in the Greater China region
Contact: LiuY@exomeasset.com
Sameh Ahsan is an Investment Analyst at Exome Asset. Mr. Ahsan joined Exome in July 2019 following the completion of his undergraduate degree in Economics and a Pre-Health Sciences concentration from New York University. Mr. Ahsan previously worked at Haver Analytics as an Economic Research Assistant and as a science researcher at the University of Oklahoma Health Sciences Center, GI Department.
Focus Area: Emerging markets healthcare investing, including in Latin America, South Africa, India, as well as gene therapy worldwide.
Contact: AhsanS@exomeasset.com
₁ AUM as of December 31, 2020